



Press release

Hørsholm
31 May 2013

ALK to present at two upcoming 2013 Investor Conferences

Page 1/1

ALK today announced that the Company will present at the Jefferies 2013 Global Healthcare Conference in New York, NY and the Goldman Sachs 34th Annual Global Healthcare Conference in Palos Verdes, CA. Jens Bager, President and CEO, will provide an overview of the Company and its key programmes at:

- Jefferies 2013 Global Healthcare Conference on Wednesday, 5 June at 3:30 PM Eastern Time
- Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, 11 June at 2.00 PM Pacific Time (5.00 PM Eastern time)

ALK's presentation at Jefferies 2013 Global Healthcare Conference will be webcast live and archived for 90 days on our website at www.alk-abello.com/investor.

ALK-Abelló A/S

Jens Bager
President and CEO

For further information please contact:

Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609-466-0466

Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck (MSD outside the USA and Canada) and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.

Press release 31 May 2013

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk.net
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16